# Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults

> **NCT04989972** · PHASE2 · WITHDRAWN · sponsor: **Wake Network, Inc.**

## Conditions studied

- Anxiety and Depression

## Interventions

- **DRUG:** PSIL428
- **DIETARY_SUPPLEMENT:** Oyster mushroom
- **DRUG:** PSIL428

## Key facts

- **NCT ID:** NCT04989972
- **Lead sponsor:** Wake Network, Inc.
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-09-15
- **Primary completion:** 2023-06-20
- **Final completion:** 2023-08-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** GCP VIOLATIONS FROM THE SPONSORS
- **Last updated:** 2022-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04989972

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04989972, "Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04989972. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*